Medtronic ’s HVAD System Just Became Less Invasive

Medtronic has gained FDA approval for a less-invasive implant approach of its HVAD System, a left ventricular assist device (LVAD) for advanced heart failure patients. The Dublin-based company picked up the technology when it acquired HeartWare in 2016. The firm said the technology is the only LVAD approved in the U.S. for implant via thoracotomy, a small lateral, surgical incision between the patient's ribs on the left side of the chest. FDA approval for HVAD implantation via thoracotomy is based on data from the LATERAL prospective clinical trial, in which 144 patients, with end-stage heart failure who were eligible for heart transplant, were enrolled at 26 centers in the U.S. and Canada. The primary endpoint of the trial demonstrated non-inferiority of the HVAD implanted in patients via thoracotomy, where survival at six months free from disabling stroke or device explant or exchange due to malfunction was achieved in 88.1% of patients. Since the success outcome exceeded the pre-specified performance goal of 77.5%, the trial achieved its primary endpoint (p=0.0012). The key secondary endpoint revealed a significant reduction in total length of hospital stay, from an average of 26.1 days down to 18 days (p
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Business Source Type: news

Related Links:

Authors: Sakhi R, Theuns DAMJ, Szili-Torok T, Yap SC Abstract INTRODUCTION: Recurrent unexplained syncope is a well-established indication for an insertable cardiac monitor (ICM). Recently, the indications for an ICM has been expanded. Areas covered: This review article discusses the current indications for ICMs and gives an overview of the latest generation of commercially available ICMs. Expert commentary: The 2018 ESC Syncope guidelines have expanded the indications for an ICM to patients with inherited cardiomyopathy, inherited channelopathy, suspected unproven epilepsy, and unexplained falls. ICMs are also inc...
Source: Expert Review of Medical Devices - Category: Medical Devices Tags: Expert Rev Med Devices Source Type: research
Authors: Mustafa ER, Tudoraşcu DR, Giucă A, Toader DM, Foarfă MC, Puiu I, Istrate-Ofiţeru AM Abstract A 46-year-old female diagnosed several years ago with arterial hypertension and an ischemic stroke with significant recovery was admitted for dyspnea on usual physical activity and fatigue. Physical examination revealed signs of heart failure with crackles on both lung bases, distented jugular veins, accentuated pulmonic valve closure (P2) and tricuspid regurgitation murmur. Echocardiography identified a large tumor in the left atrium, suggestive of atrial myxoma, which caused a severe functional mitral stenosi...
Source: Romanian Journal of Morphology and Embryology - Category: General Medicine Tags: Rom J Morphol Embryol Source Type: research
Locomotor brachii or locomotor brachialis is often described as a peripheral sign in severe aortic regurgitation or other causes of aortic runoff. It is the prominent pulsation of a usually tortuous brachial artery seen in severe aortic regurgitation. Sometimes it is called a dancing brachial artery as well. Though taken as a peripheral sign of aortic regurgitation, it is not uncommon to see a prominently pulsating tortuous brachial artery in the elderly with arteriosclerosis. In this case it is a stiffened blood vessel wall which makes the pulsation visible and more prominent. Added to this there will be isolated systoli...
Source: Cardiophile MD - Category: Cardiology Authors: Tags: Cardiology locomotor brachialis Locomotor brachii Osler's sign Source Type: blogs
Authors: Miao CQ, Lu Q, Liu P, Bai L, Qu H, Ma AQ Abstract OBJECTIVE: Nardilysin (N-arginine dibasic convertase, NRDC) is a kind of metalloendopeptidase associated with several inflammatory diseases. NRDC is reported to be eligible for early detection of acute coronary syndrome. However, the availability and effectiveness of NRDC in predicting the prognosis of patients with ST-elevation myocardial infarction has never been investigated. PATIENTS AND METHODS: From January 2010 to January 2012, the prospective observational cohort study enrolled a total of 396 STEMI patients, who were sampled with blood within 24...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
The latest estimate of attributable deaths to pollution worldwide is extraordinary: 9 million deaths annually [2]. Deaths are related to cardiovascular disorders (myocardial infarction, congestive heart failure and stroke), lung diseases and cancers. The recent Global Burden of Disease study, based on 1990 –2013 data from 188 countries demonstrated that air pollution contributes to 29.2% of the global burden of stroke. However the burden varies between 10% in high-income countries and 34% in low- and middle-income countries [3].
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Letter to the Editor Source Type: research
ConclusionIn this retrospective analysis of nearly 18,000 patients hospitalized for acute illnesses, 59.1% did not receive any VTE prophylaxis and only 7.1% received VTE prophylaxis in both the inpatient and outpatient continuum of care, despite significant VTE risk extending from hospitalization into the post-discharge period.FundingPortola Pharmaceuticals.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
Conclusion The routine use of BITA versus SITA in PVD patients does not improve long-term survival. Selective use of BITA in lower risk patients might unmask the benefits of BITA.
Source: Coronary Artery Disease - Category: Cardiology Tags: CABG Source Type: research
ConclusionsIn this simulation study, the valveless pulsatile device improves hemodynamics in HFpEF patients by increasing the total stroke volume. The hemodynamic benefits are achieved with a small device volume comparable to implantable rotary blood pumps.
Source: Cardiovascular Engineering and Technology - Category: Cardiology Source Type: research
Chief pharmaceutical officer to lead the review which will also look at efficiency and new technology Related items fromOnMedica Stroke survivors need more help taking medicine Public should ask GPs about drugs ’ relative risks and benefits GPs are letting down heart failure patients MPs want GPs to record prescription drug abuse Terminally ill patients get inadequate pain relief
Source: OnMedica Latest News - Category: UK Health Source Type: news
In conclusion, this is the first report to show that pyroptotic cell death occurs in the aging brain and that the inflammasome can be a viable target to decrease the oxidative stress that occurs as a result of aging. Reducing Levels of Protein Manufacture Slows Measures of Aging in Nematodes https://www.fightaging.org/archives/2018/12/reducing-levels-of-protein-manufacture-slows-measures-of-aging-in-nematodes/ Researchers here demonstrate that an antibiotic slows aging in nematode worms, providing evidence for it to work through a reduction in protein synthesis. Beyond a slowing of aging, one of the con...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: Canada Health | Cardiology | Cardiovascular | Clinical Trials | Heart | Heart Failure | Heart Transplant | Hospitals | Lung Transplant | Stroke | Thoracotomy | Transplant Surgery | Transplants